Evidence map›Paper›PMID 24527057›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2014

Gene Expression Profiles Underlying Selective T-Cell-Mediated Immunity Activity of a Chinese Medicine Granule on Mice Infected with Influenza Virus H1N1.

Na-Na Lu, Qi Liu, Li-Gang Gu, Shi-Jie Ge, Jun Wu, Qiu Ze-Ji, Ze-Ji Qiu, Hong-Chun Zhang, En-Xiang Chao, Zhuo-Nan Yu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Na-Na LuLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Qi LiuLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China ; Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi 030024, China.
Li-Gang GuLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Shi-Jie GeLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Jun WuLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Qiu Ze-JiLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Ze-Ji QiuDepartment of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China.
Hong-Chun ZhangDepartment of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China.
En-Xiang ChaoLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Zhuo-Nan YuLaboratory of Chinese Medicine on Viral Disease, Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Beijing University of Chinese Medicine · CNChina-Japan Friendship Hospital · CNShanxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Chinese medicine granule, Shu-Feng-Xuan-Fei (SFXF), is critical for viral clearance in early phase of influenza virus infection. In this study, 72 ICR mice were randomly divided into six groups: normal control group, virus control group, Oseltamivir group, low-dose SFXF, medium-dose SFXF, and high-dose SFXF. Mice were anesthetized and inoculated with 4LD50 of influenza virus A (H1N1) except normal control group. Oseltamivir group received 11.375 mg·kg(-1) ·d(-1) Oseltamivir Phosphate. SFXF 3.76, 1.88 and 0.94 g·kg(-1) ·d(-1) were administrated to mice in all SFXF groups. Each group was in equal dose of 0.2ml daily for 4 consecutive days. Mice were sacrificed and then total RNA was extracted in lung tissue. Some genes involved in T-cell-mediated immunity were selected by DNA microarray. These candidate genes were verified by Real-Time PCR and western immunoblotting. Compared with virus control group, in Toll-like receptor signaling pathway, 12 virus-altered genes were significantly reduced following medium-dose SFXF treatment. Eighteen antigen processing presentation-associated genes were upregulated by medium-dose SFXF. In the process of T cell receptor signaling pathway, 19 genes were downregulated by medium-dose SFXF treatment. On exploration into effector T cells activation and cytokines, all of altered genes in virus control group were reversed by medium-dose SFXF. Real-time PCR and western immunoblotting showed that the regulation of medium-dose SFXF in IL-4, IFN-γ, TNF-α, IL-1β, TLR7, MyD88, p38, and JNK was superior to Oseltamivir and high-dose SFXF group. Therefore, SFXF granules could reduce influenza infected cells and activation of T cells.

Identifiers

PMID24527057
PMCPMC3910462
OpenAlexW2005541560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.